{"protocolSection":{"identificationModule":{"nctId":"NCT04142125","orgStudyIdInfo":{"id":"CATIS-ICAD"},"organization":{"fullName":"Population Health Research Institute","class":"OTHER"},"briefTitle":"Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease","officialTitle":"Combination Anti-thrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease: Protocol for a Pilot Randomized Trial"},"statusModule":{"statusVerifiedDate":"2023-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-02-03","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-09-18","type":"ACTUAL"},"completionDateStruct":{"date":"2023-09-18","type":"ACTUAL"},"studyFirstSubmitDate":"2019-10-25","studyFirstSubmitQcDate":"2019-10-25","studyFirstPostDateStruct":{"date":"2019-10-29","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-09-24","lastUpdatePostDateStruct":{"date":"2023-09-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Population Health Research Institute","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"CATIS-ICAD is a clinical pilot study in which patients who have had a recent ischemic stroke, that is a stroke caused by a blood clot or a narrowing of the blood vessels in the brain due to the build up of plaque, will be randomly assigned to receive either low-dose rivaroxaban + aspirin or aspirin alone."},"conditionsModule":{"conditions":["Ischemic Stroke","Intracranial Atherosclerotic Disease"],"keywords":["Pilot study","Rivaroxaban","Factor Xa Inhibitors","Intracranial Atherosclerotic Disease"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"investigator-initiated, open-label, blinded endpoint assessment, controlled, randomized pilot trial (PROBE design)","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","maskingDescription":"Blinded assessment of endpoint","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":101,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Experimental (riva + ASA)","type":"EXPERIMENTAL","description":"Rivaroxaban 2.5mg bid + aspirin 81mg qd","interventionNames":["Drug: Rivaroxaban 2.5 Mg Oral Tablet bid","Drug: Acetylsalicyclic acid 81 mg tablet qd"]},{"label":"Control (ASA alone)","type":"ACTIVE_COMPARATOR","description":"Aspirin 81 mg qd","interventionNames":["Drug: Acetylsalicyclic acid 81 mg tablet qd"]}],"interventions":[{"type":"DRUG","name":"Rivaroxaban 2.5 Mg Oral Tablet bid","description":"Pts will receive rivaroxaban + aspirin","armGroupLabels":["Experimental (riva + ASA)"],"otherNames":["Xarelto"]},{"type":"DRUG","name":"Acetylsalicyclic acid 81 mg tablet qd","description":"Pts will receive ASA","armGroupLabels":["Control (ASA alone)","Experimental (riva + ASA)"],"otherNames":["Aspirin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Recruitment rate","description":"Recruitment rate of potentially eligible patients from neurology clinics","timeFrame":"From randomization to end of recruitment (2 years)"},{"measure":"Refusal rate","description":"Rate of patients who refuse to participate in the clinical trial who otherwise are eligible for the study","timeFrame":"From randomization to end of recruitment (2 years)"},{"measure":"Retention rate","description":"Rate of patients who remain in the clinical trial until EOS or qualifying event","timeFrame":"From randomization to End of Study (median 2 years)"},{"measure":"Incidence rate of Intracranial hemorrhage","description":"Rate of patients who experience an intracranial hemorrhage during the study","timeFrame":"From randomization to End of Study (median 2 years)"}],"secondaryOutcomes":[{"measure":"Major hemorrhage","description":"Major hemorrhage as defined by ISTH criteria","timeFrame":"From randomization to End of Study (median 2 years)"},{"measure":"Combination of ISTH major hemorrhages & clinically-relevant non-major hemorrhages","description":"Major hemorrhage and clinically relevant non-major as per ISTH criteria","timeFrame":"From randomization to End of Study (median 2 years)"},{"measure":"Recurrent ischemic stroke & MRI-detected incident covert brain infarction","description":"Symptomatic investigator reported ischemic stroke and MRI detected covert brain infarct as determined by MRI corelab reading baseline and end of study MRI","timeFrame":"From randomization to End of Study (median 2 years)"},{"measure":"Recurrent ischemic stroke","description":"Recurrent ischemic stroke that is restricted to the area of the qualifying stenosis","timeFrame":"From randomization to End of Study (median 2 years)"},{"measure":"Composite of stroke, myocardial infarction or vascular death","description":"Composite of stroke, MI or vascular death","timeFrame":"From randomization to End of Study (median 2 years)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age ≥ 40 years\n2. Recent brain ischemia attributed to intracranial atherosclerotic stenosis of 30-99% as evidenced by CT or MR angiography, occurring between 7 to 100 days prior to randomization and consisting of either:\n\n   1. a high-risk TIA defined as TIA with motor and/or speech involvement or\n   2. an ischemic stroke\n3. Written informed consent consistent with local regulations governing research in human subjects\n\nExclusion Criteria:\n\n1. Indication for DAPT for \\> 90 days on guideline recommendations or investigator ́s judgment; e.g., cardiac stenting.\n2. Indication for chronic anticoagulation based on guideline recommendations or investigator ́s judgment; e.g. patient with prosthetic mechanical valve, venous thromboembolism, hypercoagulable state\n3. Atrial fibrillation or a history of atrial fibrillation\n4. Intracranial arterial occlusion (e.g. 100% stenosis) responsible for the acute brain ischemia\n5. Intracranial arterial stenosis secondary to causes other than atherosclerosis\n6. Extracranial carotid artery disease ipsilateral to the qualifying brain ischemia with a plan for carotid revascularization\n7. Intraluminal thrombus\n8. Subdural hematoma within 12 months of randomization\n9. Previous spontaneous hemorrhagic stroke (e.g. intracerebral or subarachnoid hemorrhage)\n10. Traumatic brain hemorrhage within 1 month of randomization\n11. Contraindication for MRI scan (e.g. pacemaker incompatible with MRI)\n12. Advanced kidney disease (recent estimated GFR \\<30 ml per minute)\n13. Modified Rankin Scale (mRS) \\>=4 at entry\n14. Platelet count less than 100,000/mm3 at enrolment or other bleeding diathesis\n15. Uncontrollable hypertension with systolic BP/ diastolic BP consistently above180/100mmHg after treatment\n16. Known hypersensitivity to either ASA or rivaroxaban\n17. Life expectancy less than 6 months\n18. Concomitant use of strong inhibitors of both cytochrome P450 isoenzyme 3A4 (CYP3A4) and P-glycoprotein (P-gp), i.e., human immunodeficiency virus protease inhibitors and the following azole-antimycotics agents: ketoconazole, itraconazole, voriconazole, or posaconazole, if used systemically\n19. Female of childbearing potential who are not surgically sterile, or, if sexually active not willing to use adequate contraceptive measures with a failure rate less than 1% per year (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, male partner sterilization) before entry and throughout the study, as well as pregnant or breast-feeding women\n20. Inability to adhere to study procedures\n21. Close affiliation with the investigational site; e.g. a close relative of the investigator, dependent person (e.g., employee or student of the investigational site)\n22. Previous randomization to this study or participating in a study with an investigational drug or medical device at the time of randomization\n23. Antiphospholipid antibody syndrome","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Kanjana S. Perera, MD, FRCPC","affiliation":"Hamilton Health Sciences Corporation","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Alberta Health Services","city":"Calgary","state":"Alberta","zip":"T2N 2T9","country":"Canada","geoPoint":{"lat":51.05011,"lon":-114.08529}},{"facility":"University of Alberta","city":"Edmonton","state":"Alberta","zip":"T6G 2B7","country":"Canada","geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"Vancouver General Hospital","city":"Vancouver","state":"British Columbia","zip":"V5Z 1M9","country":"Canada","geoPoint":{"lat":49.24966,"lon":-123.11934}},{"facility":"Hamilton Health Sciences","city":"Hamilton","state":"Ontario","zip":"L8L 2X2","country":"Canada","geoPoint":{"lat":43.25011,"lon":-79.84963}},{"facility":"Kingston Health Sciences Centre","city":"Kingston","state":"Ontario","zip":"K7L 2V7","country":"Canada","geoPoint":{"lat":44.22976,"lon":-76.48101}},{"facility":"London Health Sciences Centre","city":"London","state":"Ontario","zip":"N6A 5A5","country":"Canada","geoPoint":{"lat":42.98339,"lon":-81.23304}},{"facility":"Ottawa Hospital Research Institute","city":"Ottawa","state":"Ontario","zip":"K1Y 4E9","country":"Canada","geoPoint":{"lat":45.41117,"lon":-75.69812}},{"facility":"Rhema Research Institute","city":"Owen Sound","state":"Ontario","zip":"N4K 6M9","country":"Canada","geoPoint":{"lat":44.56717,"lon":-80.94349}},{"facility":"Sunnybrook Health Science Centre","city":"Toronto","state":"Ontario","zip":"M4N 3M5","country":"Canada","geoPoint":{"lat":43.70011,"lon":-79.4163}},{"facility":"Toronto Western Hospital","city":"Toronto","state":"Ontario","zip":"M5T 2S8","country":"Canada","geoPoint":{"lat":43.70011,"lon":-79.4163}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M14540","name":"Recurrence","relevance":"LOW"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069552","term":"Rivaroxaban"}],"ancestors":[{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000065427","term":"Factor Xa Inhibitors"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000000925","term":"Anticoagulants"}],"browseLeaves":[{"id":"M4238","name":"Aspirin","relevance":"LOW"},{"id":"M30203","name":"Factor Xa Inhibitors","relevance":"LOW"},{"id":"M463","name":"Rivaroxaban","asFound":"Weight loss","relevance":"HIGH"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"Antipy","name":"Antipyretics"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}